Loading...
•
Jun 30
Surgery Partners Q2 2025 Earnings Report
Surgery Partners reported strong growth in Adjusted EBITDA and revenue for the second quarter of 2025, reaffirming its full-year guidance.
Key Takeaways
Surgery Partners delivered a robust second quarter in 2025, with revenue increasing by 8.4% to $826.2 million and Adjusted EBITDA growing by 9.0% to $129.0 million. The company's net loss attributable to Surgery Partners, Inc. was $2.5 million. Same-facility revenues increased by 5.1%, driven by a 3.4% increase in same-facility cases and a 1.6% increase in revenue per case. The company reaffirmed its full-year 2025 revenue and Adjusted EBITDA guidance, indicating confidence in continued operational improvements and strategic growth initiatives.
Revenue for Q2 2025 increased by 8.4% year-over-year to $826.2 million, demonstrating strong top-line growth.
Adjusted EBITDA grew by 9.0% to $129.0 million in Q2 2025, reflecting improved operational performance and margin expansion.
Same-facility revenues increased by 5.1%, driven by a 3.4% rise in same-facility cases and a 1.6% increase in revenue per case, indicating healthy organic growth.
The company reaffirmed its full-year 2025 revenue guidance of $3.30 billion to $3.45 billion and Adjusted EBITDA guidance of $555 million to $565 million, signaling confidence in future performance.
Surgery Partners
Surgery Partners
Forward Guidance
Surgery Partners reaffirmed its full-year 2025 guidance for revenue and Adjusted EBITDA, indicating confidence in continued growth and operational improvements.
Positive Outlook
- Reaffirmed full-year 2025 revenue guidance in the range of $3.30 billion to $3.45 billion.
- Reaffirmed full-year 2025 Adjusted EBITDA guidance in the range of $555 million to $565 million.
- Guidance implies continued margin expansion, reflecting ongoing operating system improvements.
- Expects integration benefits from recent acquisitions to contribute to performance.
- Anticipates contributions from de novo facilities expected to open in 2025.